Navigation Links
Advanced CT scans accurately assess coronary blockages
Date:8/28/2012

An ultra-fast, 320-detector computed tomography (CT) scanner can accurately sort out which people with chest pain need or don't need an invasive procedure such as cardiac angioplasty or bypass surgery to restore blood flow to the heart, according to an international study. Results of the study, which involved 381 patients at 16 hospitals in eight countries, are scheduled to be presented at the European Society of Cardiology Congress in Munich, Germany, on August 28.

"The CORE 320 study is the first prospective, multicenter study to examine the diagnostic accuracy of CT for assessing blockages in blood vessels and determining which of those blockages may be preventing the heart from getting adequate blood flow," says Joao A. C. Lima, M.D., senior author of the study and professor of medicine and radiology at the Johns Hopkins University School of Medicine. "We found an excellent correlation in results when we compared the 320-detector CT testing with the traditional means of assessment using a stress test with imaging and cardiac catheterization."

The study findings, says Lima, would apply to people who have chest pain but are not having a heart attack. Many people in that situation are sent to a cardiac catheterization laboratory for further evaluation with angiography, an invasive test to look for blockages in the coronary arteries using dye and special X-rays. About 30 percent of people who have such catheterization are found to have minimal disease or no blockage requiring an intervention to open or bypass the vessel.

Lima explains that a nuclear medicine stress test with imaging, known as SPECT, shows reduced blood flow to the heart without indicating the number or specific location of blockages.

The 381 patients who completed the study had traditional SPECT tests and invasive angiography. They also had two types of tests with a non-invasive 320-detector CT scanner. In the first CT test, the scanner was used to see the anatomy of vessels to assess whether and where there were blockages. That test is known as CTA, in which the "A" stands for angiography. Then, in a second CT test with the same machine, patients were given a vasodilator, a medicine that dilates blood vessels and increases blood flow to the heart in ways similar to what happens during a stress test. The second test is called CTP, with the "P" standing for perfusion.

According to lead author Carlos E. Rochitte, M.D., a cardiologist at the Instituto do Coracao in Sao Paulo, Brazil, "We found that the 320-detector CT scanner allowed us to see the anatomy of the blockages as well as determine whether the blockages were causing a lack of perfusion to the heart. We were therefore able to correctly identify the patients who needed revascularization within 30 days of their evaluation."

"Many patients are sent for an angioplasty when they may not need it. Our ultimate goal is to have more certainty about which patients having chest pain without evidence of a heart attack need an invasive procedure to open an arterial blockage," says cardiologist Richard George, M.D., assistant professor of medicine at the Johns Hopkins University School of Medicine and a co-author of the study.

"The CTP test added significant information about the patients' conditions and boosted our ability to identify those whose blockages were severe enough to reduce blood flow to the heart," adds George, who developed the CTP method with Lima.

The 320-detector CT provides a complete picture of the heart by making just one revolution around the body. The researchers say the two tests combined CTA and CTP still produce less radiation than a scan with the 64-detector in widespread use today.

"In our study, the amount of radiation exposure to patients from the two 320-detector CT scanner tests was half the amount they received as a result of the traditional evaluation methods the angiogram and nuclear medicine stress test combined," says Lima.

The researchers will continue to follow the patients in the study for up to five years, looking for any heart-related events such as heart attacks, as well as hospital admissions, procedures or surgeries.

Hospitals that participated in the CORE 320 study are located in the United States, Germany, Canada, Brazil, the Netherlands, Denmark, Japan and Singapore. Images obtained during the study were evaluated in core laboratories at Johns Hopkins and at the Brigham and Women's Hospital in Boston. The study was sponsored by Toshiba Medical Systems.

Johns Hopkins researchers collaborated with Toshiba on the development of the 320-detector CT scanner used in the study. In 2007, Johns Hopkins was one of three sites that participated in worldwide beta testing of the scanner that served as the prototype of the 320-detector system. Feedback provided by Johns Hopkins researchers was instrumental in the development of the scanner, which is now the only 320-detector CT scanner on the market.


'/>"/>

Contact: Ellen Beth Levitt
eblevitt@jhmi.edu
Johns Hopkins Medicine
Source:Eurekalert

Related medicine news :

1. Renal denervation gives better outcomes than drugs in advanced heart failure
2. New Drug Appears to Extend Survival in Advanced Prostate Cancer Patients
3. Newer Bone Drug Better for Advanced Breast Cancer Patients: Study
4. Drug May Aid People With Advanced Thyroid Cancer
5. Imaging Tests Up Among Advanced Cancer Patients
6. Clinical trial seeks to cure advanced Crohns disease using bone marrow transplant
7. Lack of insurance linked to advanced stage cervical cancer
8. Ecig Advanced Sponsors Lexington's First Annual Vaping Event
9. Advanced Osteoarthritis Of The Knee Is Now Being Treated With Regenerative Medicine At The Center For Regenerative Medicine
10. San Francisco’s Advanced Male Medical Center Announces Discount, Discusses Erectile Dysfunction
11. GW researchers discover biomarker for advanced bile duct fibrosis and bile duct cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to take ... an inventor from Austin, Texas, has identified a solution. , She developed a prototype ... restricted lighting. As such, it eliminates the need to turn on a light when ...
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: